Review



pearson’s correlation coefficient(r) calculated in graphpad prism  (GraphPad Software Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GraphPad Software Inc pearson’s correlation coefficient(r) calculated in graphpad prism
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson’s Correlation Coefficient(R) Calculated In Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pearson’s correlation coefficient(r) calculated in graphpad prism/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    pearson’s correlation coefficient(r) calculated in graphpad prism - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer"

    Article Title: Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer

    Journal: Nature Communications

    doi: 10.1038/s41467-025-59588-3

    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Figure Legend Snippet: a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.

    Techniques Used: Comparison, Clinical Proteomics, Two Tailed Test



    Similar Products

    pearson’s correlation coefficient(r) calculated in graphpad prism  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson’s correlation coefficient(r) calculated in graphpad prism
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson’s Correlation Coefficient(R) Calculated In Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pearson’s correlation coefficient(r) calculated in graphpad prism/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    pearson’s correlation coefficient(r) calculated in graphpad prism - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    pearson correlation coefficient (r) analysis and p value (t-distribution with n-2 degrees of freedom) calculation  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson correlation coefficient (r) analysis and p value (t-distribution with n-2 degrees of freedom) calculation
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson Correlation Coefficient (R) Analysis And P Value (T Distribution With N 2 Degrees Of Freedom) Calculation, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pearson correlation coefficient (r) analysis and p value (t-distribution with n-2 degrees of freedom) calculation/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficient (r) analysis and p value (t-distribution with n-2 degrees of freedom) calculation - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    pearson's correlation coefficient (r) with p values calculated using graphpad prism  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson's correlation coefficient (r) with p values calculated using graphpad prism
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson's Correlation Coefficient (R) With P Values Calculated Using Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pearson's correlation coefficient (r) with p values calculated using graphpad prism/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    pearson's correlation coefficient (r) with p values calculated using graphpad prism - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    pearson correlation coefficient (r) and p-value calculated with graphpad prism  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson correlation coefficient (r) and p-value calculated with graphpad prism
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson Correlation Coefficient (R) And P Value Calculated With Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pearson correlation coefficient (r) and p-value calculated with graphpad prism/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficient (r) and p-value calculated with graphpad prism - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    pearson correlation coefficients (r) calculated for pairwise combinations of relative gene quantities  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson correlation coefficients (r) calculated for pairwise combinations of relative gene quantities
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson Correlation Coefficients (R) Calculated For Pairwise Combinations Of Relative Gene Quantities, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pearson correlation coefficients (r) calculated for pairwise combinations of relative gene quantities/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficients (r) calculated for pairwise combinations of relative gene quantities - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    pearson’s correlation coefficient (r) calculation and linear regression analysis  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson’s correlation coefficient (r) calculation and linear regression analysis
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson’s Correlation Coefficient (R) Calculation And Linear Regression Analysis, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pearson’s correlation coefficient (r) calculation and linear regression analysis/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    pearson’s correlation coefficient (r) calculation and linear regression analysis - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    pearson correlation coefficient (r) and p-value calculation  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson correlation coefficient (r) and p-value calculation
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson Correlation Coefficient (R) And P Value Calculation, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pearson correlation coefficient (r) and p-value calculation/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficient (r) and p-value calculation - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    pearson’s correlation coefficient ( r ) calculation and linear regression analysis  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson’s correlation coefficient ( r ) calculation and linear regression analysis
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson’s Correlation Coefficient ( R ) Calculation And Linear Regression Analysis, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pearson’s correlation coefficient ( r ) calculation and linear regression analysis/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    pearson’s correlation coefficient ( r ) calculation and linear regression analysis - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    pearson correlation coefficient (r-value) calculation  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson correlation coefficient (r-value) calculation
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson Correlation Coefficient (R Value) Calculation, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pearson correlation coefficient (r-value) calculation/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficient (r-value) calculation - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    pearson correlation coefficient (r 2 ) and statistical significance ( p -value) calculation  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson correlation coefficient (r 2 ) and statistical significance ( p -value) calculation
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson Correlation Coefficient (R 2 ) And Statistical Significance ( P Value) Calculation, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pearson correlation coefficient (r 2 ) and statistical significance ( p -value) calculation/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficient (r 2 ) and statistical significance ( p -value) calculation - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer

    doi: 10.1038/s41467-025-59588-3

    Figure Lengend Snippet: a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.

    Article Snippet: The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies.

    Techniques: Comparison, Clinical Proteomics, Two Tailed Test